Fmoc-His(Trt)-OH

Fmoc-His(Trt)-OH (CAS 109425‑51‑6) is the preferred N‑α‑Fmoc/Nᵢₘ‑trityl‑protected histidine derivative for Fmoc solid‑phase peptide synthesis (SPPS). Fmoc-His(Trt)-OH is the preferred building block for incorporating histidine residues in Fmoc SPPS, as the Trt group provides robust piperidine stability while enabling mild acid cleavage. Compared to Fmoc‑His(Boc)‑OH, Fmoc-His(Trt)-OH offers cost‑effectiveness and streamlined simultaneous deprotection. Moreover, premium grades of Fmoc-His(Trt)-OH feature dipeptide impurities ≤ 0.1 % (a/a) and enantiomeric purity ≥ 99.8 %, ensuring high crude peptide purity and batch‑to‑batch consistency for both R&D and cGMP production. With a molecular weight of 619.71 g/mol and supplied as a white to off‑white powder, Fmoc-His(Trt)-OH is the building block of choice for researchers and manufacturers requiring reliable histidine incorporation in synthetic peptides.

Product Parameters

Why Cosperpharm?

When your histidine‑containing peptide demands minimal racemization and maximum coupling efficiency, Cosperpharm delivers Fmoc-His(Trt)-OH with the purity, documentation, and supply reliability that pharmaceutical customers require.

Histidine incorporation begins with the right protecting group. The histidine imidazole side chain is notoriously prone to racemization and side reactions during peptide synthesis. Fmoc-His(Trt)-OH features the bulky trityl (Trt) protecting group, which effectively suppresses racemization and Nπ–Nτ tautomerization during activation and coupling. Any impurity or incorrect protection in this building block will compromise peptide quality. Cosperpharm‘s analytical release protocol includes HPLC purity (≥ 99.0 %), enantiomeric purity (≥ 99.8 % a/a), dipeptide impurities (≤ 0.1 %), water content (Karl Fischer), and identity confirmation — because your histidine‑peptide integrity depends on the quality of this building block.

Documentation that supports your regulatory filings. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers manufacturing histidine‑containing peptide therapeutics, Cosperpharm provides DMF‑ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

Flexible supply across all development stages. Cosperpharm supplies Fmoc-His(Trt)-OH from 1g–50g quantities for peptide screening and method development, to 100g–500g batches for process validation, to 25kg drums for commercial peptide manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

Technical support for the full SPPS cascade. Our peptide chemistry team can advise on coupling conditions optimized for histidine residues, analytical methods for detecting racemisation, and the simultaneous deprotection of Trt and side‑chain protecting groups during TFA cleavage — because we have worked extensively with this protected amino acid across multiple peptide manufacturing campaigns.

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and academic research institutions worldwide, with full customs documentation included. Volume discounts apply at kilogram scales, and we communicate lead times upfront — no hidden fees, no unexpected delays.

Synthetic Route

Synthesis via Trityl Protection of Imidazole followed by Fmoc Protection

Fmoc-His(Trt)-OH is synthesized through a two‑step protection strategy, with the imidazole side chain protected first (Trt) followed by N‑α‑Fmoc protection:

Step 1 — Trityl protection of histidine: L‑Histidine is reacted with trityl chloride (Trt‑Cl) in the presence of a base such as triethylamine or DIEA in a suitable solvent (e.g., DMF or DCM). The trityl group selectively protects the Nᵢₘ (τ‑nitrogen) of the imidazole ring, forming Nᵢₘ‑trityl‑L‑histidine.

Step 2 — Fmoc protection: The N‑α‑amino group of Nᵢₘ‑trityl‑L‑histidine is protected with Fmoc‑Cl or Fmoc‑OSu under Schotten‑Baumann conditions (aqueous base/organic solvent mixture). The pH is maintained at 8–9, and the reaction is stirred until protection is complete.

Step 3 — Acidification and purification: The reaction mixture is acidified to pH 2–3, and the product is extracted into an organic solvent. The crude product is purified by recrystallisation or column chromatography to achieve ≥ 99.0 % HPLC purity.

Storage Conditions

Store Fmoc-His(Trt)-OH in a tightly sealed container at 2–8 °C (long‑term storage) or +20 °C (short‑term storage) in a clean, dry, well‑ventilated area. Keep the container protected from light and moisture. The compound is hygroscopic and should be protected from atmospheric moisture. For long‑term storage (>12 months), storage at –20 °C under inert atmosphere is recommended. Do not store near strong oxidizing agents, strong bases, or sources of ignition.

Shelf life: Typically 2–3 years when stored at 2–8 °C in a sealed container under inert atmosphere. Accelerated stability data and long‑term stability summaries are available upon request to support regulatory filings.

Handling precautions: Use in a fume hood where appropriate. Wear chemical‑resistant gloves, safety goggles, and a lab coat. Avoid generating dust. Do not eat, drink or smoke in work areas. After handling, wash hands thoroughly. Refer to the Safety Data Sheet (SDS) for complete safety information.

Contact Us

Need Fmoc-His(Trt)-OH for your histidine‑rich peptide synthesis or cGMP production campaign? Cosperpharm is your trusted partner for high‑purity Fmoc‑protected amino acids with comprehensive documentation and flexible supply options. Contact us today to request a quote, obtain a Certificate of Analysis, or discuss custom synthesis and packaging requirements. Our dedicated customer support team is ready to assist with product specifications, regulatory documentation, and shipping coordination. From early‑stage research to commercial manufacturing, we’re here to support your success.